Four Basic Principles

Principle 1: To develop a product with extreme safety.

The organization is planning to develop a product consisting of active ingredients with uncompromised long-standing safety documentation.

 

Principle 2: To develop a product that can be manufactured at a very low cost.

The active ingredients will be manufactured via standard process chemistry. Our delivery technology will involve safe excipients, which are also very inexpensive to manufacture.

 

Principle 3: To develop a product that is compatible with pediatric use.

The organization is developing intellectual property around novel packaging formats combined with a new mini-particle technology that allows flexible dosing, taste-free coating and provides extended release compatible with a single daily dose administration.

 

Principle 4: To make the program self-sustainable through licensing agreements with for-profit industry. Releef is planning to out-license the rights to sell products based on our intellectual property to for-profit partners. The partners will have rights to manufacture, distribute, and sell products in developed countries. In return, Releef will obtain a royalty stream that can be used for purchase of product for humanitarian use. We believe that for-profit mechanisms are the best way to ensure sustainability.

Home    |     About Us     |     R&D     |     News & Media     |     Participate     |     Contact Us  

the

initiative

ReLeef

Our Approach

 

The Releef Initiative is a non-profit pharmaceutical corporation that operates as a virtual R&D organization, i.e. all research and development is conducted by outsourcing. By working in this mode, Releef avoids time- and cash-consuming build-up and maintenance of internal infrastructure. The organization is managed as a global network with representatives in US, Sweden and Russia. The corporate headquarter is in San Diego, California.

 

R&D